See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Taisheng Li
1,Department of Infection Diseases, Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing.2,Clinical Immunology Center,Chinese Academy of Medical Sciences,Beijing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7050-5675
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The impact of HIV-1 subtype (CRF01_AE and non-CRF01_AE) on HIV-1 DNA levels in HIV-1 chronically infected patients with suppressive antiretroviral therapy (ART) remains poorly understood. To evaluate the correlation of HIV-1 subtype with DNA level, and identify baseline predictors of HIV-1 DNA decay. Methods : ART-naïve HIV-1-infected patients from two large multi-center studies in China were classified into CRF01_AE and non-CRF01_AE subtype groups. Peripheral blood samples were collected at baseline and week 12, 24, 48 and 96 after ART initiation and total HIV-1 DNA levels were quantified by real-time PCR. HIV-1 DNA levels at week 96 were categorized into high, moderate, and low levels, reflecting HIV-1 DNA ≥ 3, 2–3, ≤ 2 log 10 copies/10 6 PBMCs, respectively , and the corresponding proportion of CRF01_AE and non-CRF01_AE subtype were compared. The baseline predictors of low HIV-1 total DNA levels (≤ 2 log 10 copies/10 6 PBMCs) at week 96 were evaluated using a logistic regression model. Results: Compared to the non-CRF01_AE subtypes (n=185), patients with CRF01_AE subtype (n=188) harboured a higher level of HIV-1 DNA (median: 3.19 vs. 2.95 log 10 copies/10 6 PBMCs, P < 0.001) prior to treatment. After 96 weeks of ART, HIV-1 DNA levels remained higher in the CRF01_AE subtype group (median: 2.63 vs. 2.39 log 10 copies/10 6 PBMCs, P = 0.002). There was no significant difference in the proportion of patients achieving high (22.3% vs. 14.6%, P = 0.054), moderate (59.6% vs. 60.5%, P = 0.849) and low levels (18.1% vs 24.9%, P = 0.111) between CRF01_AE and non-CRF01_AE groups. In the multivariable analysis, baseline HIV-1 DNA level and CD4 + T cell count but not the subtype were independent risk factors for achieving HIV-1 DNA level ≤ 2 log 10 copies/10 6 PBMCs. Conclusion: HIV-1 CRF01_AE subtype is neither correlated with HIV-1 DNA reservoir decline nor a prognostic factor for achieving lower HIV-1 DNA levels (≤ 2 log 10 copies/10 6 PBMCs) after ART. However, higher HIV-1 DNA level in HIV-1 CRF01_AE patients should be aroused much attention and strengthen surveillance during ART.
Keywords
HIV, CRF01_AE, DNA reservoir, antiretroviral therapy
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
Version 3
Posted 13 Jan, 2020
No community comments so far
Submission checks complete
On 10 Jan, 2020
Editorial decision: Accept
On 09 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 03 Jan, 2020
Review #2 received
Received 09 Dec, 2019
Reviewer #1 agreed
On 26 Nov, 2019
Reviewer #2 agreed
On 26 Nov, 2019
Review #1 received
Received 26 Nov, 2019
Reviewers invited
Invitations sent on 25 Nov, 2019
Editor assigned
On 15 Nov, 2019
Submission checks complete
On 14 Nov, 2019
Editor invited
On 14 Nov, 2019
No comments provided
Editorial decision: Major revision
On 14 Oct, 2019
Review #2 received
Received 11 Oct, 2019
Reviewer #2 agreed
On 30 Sep, 2019
Review #1 received
Received 16 Aug, 2019
Reviewer #1 agreed
On 17 Jul, 2019
Reviewers invited
Invitations sent on 14 Jul, 2019
Editor assigned
On 01 Jul, 2019
Submission checks complete
On 01 Jul, 2019
Editor invited
On 01 Jul, 2019
First submitted
On 23 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Taisheng Li
1,Department of Infection Diseases, Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing.2,Clinical Immunology Center,Chinese Academy of Medical Sciences,Beijing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7050-5675
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
Version 3
Posted 13 Jan, 2020
No community comments so far
Submission checks complete
On 10 Jan, 2020
Editorial decision: Accept
On 09 Jan, 2020
No comments provided
Editorial decision: Minor revision
On 03 Jan, 2020
Review #2 received
Received 09 Dec, 2019
Reviewer #1 agreed
On 26 Nov, 2019
Reviewer #2 agreed
On 26 Nov, 2019
Review #1 received
Received 26 Nov, 2019
Reviewers invited
Invitations sent on 25 Nov, 2019
Editor assigned
On 15 Nov, 2019
Submission checks complete
On 14 Nov, 2019
Editor invited
On 14 Nov, 2019
No comments provided
Editorial decision: Major revision
On 14 Oct, 2019
Review #2 received
Received 11 Oct, 2019
Reviewer #2 agreed
On 30 Sep, 2019
Review #1 received
Received 16 Aug, 2019
Reviewer #1 agreed
On 17 Jul, 2019
Reviewers invited
Invitations sent on 14 Jul, 2019
Editor assigned
On 01 Jul, 2019
Submission checks complete
On 01 Jul, 2019
Editor invited
On 01 Jul, 2019
First submitted
On 23 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Infectious Diseases.
Background: The impact of HIV-1 subtype (CRF01_AE and non-CRF01_AE) on HIV-1 DNA levels in HIV-1 chronically infected patients with suppressive antiretroviral therapy (ART) remains poorly understood. To evaluate the correlation of HIV-1 subtype with DNA level, and identify baseline predictors of HIV-1 DNA decay. Methods : ART-naïve HIV-1-infected patients from two large multi-center studies in China were classified into CRF01_AE and non-CRF01_AE subtype groups. Peripheral blood samples were collected at baseline and week 12, 24, 48 and 96 after ART initiation and total HIV-1 DNA levels were quantified by real-time PCR. HIV-1 DNA levels at week 96 were categorized into high, moderate, and low levels, reflecting HIV-1 DNA ≥ 3, 2–3, ≤ 2 log 10 copies/10 6 PBMCs, respectively , and the corresponding proportion of CRF01_AE and non-CRF01_AE subtype were compared. The baseline predictors of low HIV-1 total DNA levels (≤ 2 log 10 copies/10 6 PBMCs) at week 96 were evaluated using a logistic regression model. Results: Compared to the non-CRF01_AE subtypes (n=185), patients with CRF01_AE subtype (n=188) harboured a higher level of HIV-1 DNA (median: 3.19 vs. 2.95 log 10 copies/10 6 PBMCs, P < 0.001) prior to treatment. After 96 weeks of ART, HIV-1 DNA levels remained higher in the CRF01_AE subtype group (median: 2.63 vs. 2.39 log 10 copies/10 6 PBMCs, P = 0.002). There was no significant difference in the proportion of patients achieving high (22.3% vs. 14.6%, P = 0.054), moderate (59.6% vs. 60.5%, P = 0.849) and low levels (18.1% vs 24.9%, P = 0.111) between CRF01_AE and non-CRF01_AE groups. In the multivariable analysis, baseline HIV-1 DNA level and CD4 + T cell count but not the subtype were independent risk factors for achieving HIV-1 DNA level ≤ 2 log 10 copies/10 6 PBMCs. Conclusion: HIV-1 CRF01_AE subtype is neither correlated with HIV-1 DNA reservoir decline nor a prognostic factor for achieving lower HIV-1 DNA levels (≤ 2 log 10 copies/10 6 PBMCs) after ART. However, higher HIV-1 DNA level in HIV-1 CRF01_AE patients should be aroused much attention and strengthen surveillance during ART.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Loading...